Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Stroke

• Publication date

  1995-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00008506-199507000-00009PMID 7709405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delayed Therapy of Experimental Ischemia With Competitive N‐Methyl‐D‐Aspartate Antagonists in Rabbits

  1993cited by this paper
• Neuroprotective effects of glutamate antagonists and extracellular acidity.

  1993cited by this paper
• The Effects of a Competitive NMDA Receptor Antagonist (CGS-19755) on Cerebral Blood Flow and pH in Focal Ischemia

  1991cited by this paper
• Changes in extracellular amino acid neurotransmitters produced by focal cerebral ischemia.

  1990cited by this paper
• N‐Methyl‐D‐Aspartate antagonist reduces stroke size and regional glucose metabolism

  1990cited by this paper
• CGS‐19755, A competitive NMDA receptor antagonist, reduces calcium‐calmodulin binding and improves outcome after global cerebral ischemia

  1990cited by this paper
• The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils.

  1988cited by this paper
• Glutamate and the pathophysiology of hypoxic–ischemic brain damage

  1986cited by this paper
• Glutamate neurotoxicity in cortical cell culture is calcium dependent.

  1985cited by this paper

• Exploring NMDAR pathways in ischemic stroke: implications for neurotoxic and neuroprotective mechanisms and therapeutic strategies

  2025cites this paper
• Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An In-depth Review.

  2025cites this paper
• Back Again to the Future: A New Era for Cerebroprotection

  2025cites this paper
• Volumetric apparent diffusion coefficient histogram analysis in term neonatal asphyxia treated with hypothermia.

  2024cites this paper
• 2-BFI protects against ischemic stroke by selectively acting on NR2B-containing NMDA receptors.

  2024cites this paper
• Glutamate acts on acid-sensing ion channels to worsen ischaemic brain injury

  2024cites this paper
• IC87201, a PSD-95/nNOS Inhibitor, Ameliorates Heart Rate Variability in the Rat Model of Middle Cerebral Artery Occlusion

  2023cites this paper
• The most prominent electrophysiological e ff ect of ketamine is not su ffi cient to cause anesthesia

  2023cites this paper
• Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions

  2022cites this paper
• Activation of basolateral amygdala to anterior cingulate cortex circuit alleviates MK-801 induced social and cognitive deficits of schizophrenia

  2022cites this paper
• Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases

  2022cites this paper
• Cerebroprotection for Acute Ischemic Stroke

  2021cites this paper
• Development of Peptide-Based PDZ Domain Inhibitors.

  2021cites this paper
• The Negative Allosteric Modulator EU1794-4 Reduces Single-Channel Conductance and Ca2+ Permeability of GluN1/GluN2A N-Methyl-d-Aspartate Receptors

  2021influential citation
• Therapeutic time windows of compounds against NMDA receptors signaling pathways for ischemic stroke

  2021cites this paper
• Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors.

  2021cites this paper
• Fifty Years of Acute Ischemic Stroke Treatment: A Personal History

  2021cites this paper
• Synthetic structural modifications of neurosteroid pregnanolone sulfate: Assessment of neuroprotective effects in vivo.

  2020cites this paper
• Pharmacological characterizations of the 'legal high' fluorolintane and isomers.

  2019cites this paper
• The receptor‐receptor interaction between mGluR1 receptor and NMDA receptor: a potential therapeutic target for protection against ischemic stroke

  2019cites this paper
• NMDA Antagonists for Treatment-Resistant Depression.

  2019cites this paper
• Scaling Synapses in the Presence of HIV

  2018cites this paper
• Targeting NMDA receptors in stroke: new hope in neuroprotection

  2018cites this paper
• Effect of Recombinant Insulin-like Growth Factor-2 Injected into the Hippocampus on Memory Impairment Following Hippocampal Intracerebral Hemorrhage in Rats

  2018cites this paper
• Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor‐mediated synaptic plasticity

  2018cites this paper
• A Review of Neuroinflammatory Mechanisms in Ischemic Stroke: Background and Therapeutic Approaches

  2017cites this paper
• Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke.

  2017cites this paper
• History of Neuroprotection: Trials and Tribulations

  2017cites this paper
• Targeting PSD-95 as a Novel Approach in the Treatment of Stroke

  2017cites this paper
• Novel Interventions for Stroke: Nervous System Cooling

  2016cites this paper
• Glutamate Pharmacological Models Relevant to Schizophrenia and Psychosis: Can a Receptor Occupancy Normalization Approach Reduce the Gap between Animal and Human Experiments?

  2016cites this paper
• A Nonrewarding NMDA Receptor Antagonist Impairs the Acquisition, Consolidation, and Expression of Morphine Conditioned Place Preference in Mice

  2016cites this paper
• Low doses of the mycotoxin citrinin protect cortical neurons against glutamate-induced excitotoxicity.

  2016cites this paper
• Enabling dual cellular destinations of polymeric nanoparticles for treatment following partial injury to the central nervous system.

  2016cites this paper
• Imbalanced kynurenine pathway in schizophrenia and depression : immunological and genetic aspects

  2016cites this paper
• Galacto-N-biose is neuroprotective against glutamate-induced excitotoxicity in vitro.

  2016cites this paper
• The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015

  2016cites this paper
• Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview.

  2015cites this paper
• eview nderstanding history , and not repeating it . Neuroprotection for cute ischemic stroke : From review to preview

  2015cites this paper
• Ketamine and phencyclidine: the good, the bad and the unexpected

  2015cites this paper
• Drug development in schizophrenia: are glutamatergic targets still worth aiming at?

  2015cites this paper
• The Ischemic Penumbra and Cell Survival

  2015cites this paper
• 1H-NMR-Based Metabolomic Analysis of Cerebrospinal Fluid From Adult Bilateral Moyamoya Disease

  2015cites this paper
• Apparent diffusion coefficient histogram analysis of neonatal hypoxic–ischemic encephalopathy

  2014cites this paper
• AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.

  2014cites this paper
• Excitotoxicity and stroke: identifying novel targets for neuroprotection.

  2014cites this paper
• Translational research in acute central nervous system injury: lessons learned and the future.

  2014cites this paper
• Cellular Origin and Regulation of D-and L-Serine in in Vitro and in Vivo Models of Cerebral Ischemia

  2014cites this paper
• Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

  2013cites this paper
• Examining the potential of PGE₂ receptor EP₄ as a neuroprotective target following ischaemic injury

  2013cites this paper
• Guideline for Healthcare Professionals From the American Heart Association/American Guidelines for the Early Management of Patients With Acute Ischemic Stroke : A

  2013cites this paper
• Drug Therapy in Stroke: From Preclinical to Clinical Studies

  2013cites this paper
• Neuroprotective Therapies In Stroke

  2012cites this paper
• Wind-Up of Spinal Neurons Contributes To Supramaximal Volitional Torque in Human Spinal Cord Injury

  2012cites this paper
• Informed Consent: The Rate-Limiting Step in Acute Stroke Trials

  2011cites this paper
• Stroke as a complication of acute coronary syndrome: questions to the neurologist

  2011cites this paper
• 53 – Pharmacologic Modification of Acute Cerebral Ischemia

  2011cites this paper
• Memantine prevents aluminum-induced cognitive deficit in rats.

  2011cites this paper
• An Effective Neuroprotective Treatment in Ischemic Stroke and Cerebral Trauma with Low Doses of L-Arginine, Lamotrigine and Tianeptine

  2011cites this paper
• The kynurenine pathway and development of schizophrenia : Immunological and genetic aspects

  2011cites this paper
• Clinical trials for cytoprotection in stroke

  2011cites this paper
• Kynurenic acid in psychiatric disorders : studies on the mechanisms of action

  2010cites this paper
• Clinical Trials with Drugs Targeting Ionic Channels, Antiporters, and Pumps in Ischemic Stroke

  2009cites this paper
• Is xenon a future neuroprotectant

  2009cites this paper
• Approaches to neuroprotective and reperfusion injury therapy.

  2009cites this paper
• Therapeutic potential of novel glutamate receptor antagonists in migraine

  2009cites this paper
• Neuroprotection for ischemic stroke: past, present and future.

  2008cites this paper
• Glutamate Receptor Antagonists and the Treatment of Neurological Disorders

  2008cites this paper
• Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain.

  2008cites this paper
• Perseverance furthers? The role of the drug hunter in the postgenomic era.

  2008cites this paper
• Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy

  2007cites this paper
• Neurotransmitter receptor binding in the posterior cingulate cortex in schizophrenia and in the phencyclidine mouse model: an exploration of the NMDA hypofunction hypothesis of schizophrenia

  2007cites this paper
• The kynurenic acid hypothesis of schizophrenia.

  2007cites this paper
• Guidelines for the Early Management of Adults With Ischemic Stroke

  2007cites this paper
• Tricyclic quinoxalinediones, aza-kynurenic acids, and indole-2-carboxylic acids as in vivo active NMDA-glycine antagonists.

  2006cites this paper
• Schizophrenie, Entzündung und glutamaterge Neurotransmission: ein pathophysiologisches Modell

  2006cites this paper
• Low Doses of Memantine Disrupt Memory in Adult Rats

  2006cites this paper
• Endogenous kynurenic acid and schizophrenia : Physiological and pharmacological aspects

  2006cites this paper
• Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission

  2006cites this paper
• Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons

  2006cites this paper
• Sarcosine based indandione hGlyT1 inhibitors.

  2006cites this paper
• Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.

  2006cites this paper
• Cetamina: aspectos gerais e relação com a esquizofrenia

  2005cites this paper
• Alternativa terapeutica en la isquemia cerebral empleando la Eritropoyetina humana recombinante (rHu-EPO CIM) como neuroprotector.

  2005cites this paper
• Glutamate Receptor Pharmacology: Lessons Learned from the Last Decade of Stroke Trials

  2005cites this paper
• The importance of voltage-dependent sodium channels in cerebral ischaemia

  2005cites this paper
• Neuroprotection: Where Are We Going?

  2005cites this paper
• The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability Study

  2005cites this paper
• Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia.

  2005cites this paper
• Approaches to Neuroprotection and Recovery Enhancement After Acute Stroke

  2005cites this paper
• Glutamate and anxiety.

  2004cites this paper
• The search for neuroprotective strategies in stroke.

  2004cites this paper
• Endogenous kynurenic acid disrupts prepulse inhibition.

  2004cites this paper
• Chapter 53 – Pharmacologic Modification of Acute Cerebral Ischemia

  2004cites this paper
• Prolonged exposure to inhalational anesthetic nitrous oxide kills neurons in adult rat brain.

  2003cites this paper
• Kynurenic acid and schizophrenia.

  2003cites this paper
• Neuroprotective effects of N-methyl-D-aspartate receptor antagonist on aspartate induced neurotoxicity in the spinal cord in vivo.

  2003cites this paper
• Ionotropic glutamate receptor biology: effect on synaptic connectivity and function in neurological disease.

  2003cites this paper
• Acute Ischemic Stroke Treatment: An Emergency B. Therapy

  2003cites this paper
• Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit

  2003cites this paper